Open Access Open Access  Restricted Access Subscription or Fee Access

An Open Clinical Study to Evaluate the Efficacy of Shirobasti and Nasya with and without Levodopa in the Management of Kampavata w.s.r. to Parkinson’s Disease (PD)

Jatinder Verma, Gopesh Mangal, Deepak Jain


Background: Kampavata (Parkinson’s disease), considered as Vata Nanatamaja disorder, is the most common progressive neurodegenerative disorder characterized by bradykinesia, resting tremors, muscular rigidity, shuffling gait and flexed posture accompanied by a variety of non-motor symptoms, including autonomic, sensory, sleep, cognitive and psychiatric disturbances. Aim and Objectives: To study the effect of Shirobasti and Nasya in the management of Kampavata (PD) with levodopa and without levodopa. Materials and Methods: The present clinical trial was an open label, interventional prospective research, conducted on 30 subjects of Kampavata (PD) who had fulfilled the inclusion criteria. Subjects were divided into two groups, having 15 cases in each group and treated with Shirobasti and Nasya with Ksheerbala Taila for 14 days. Patients of Group A were allowed to continue levodopa in a fixed dose during the trial whereas in Group B, levodopa was not given to the subjects. Total duration of study was 45 days. Assessment was done on the basis of Unified Parkinson Disease Rating Scale (UPDRS) scale (modified) before, after the treatment and after follow-up. Ethical clearance and written consent was obtained. A detailed case record form and patient information sheet was prepared for the study. Results: The comparative effect of both the procedures showed more significant results in Group B (without levodopa) than Group A (with levodopa). Conclusion: In Group A, significant results were found in Stambha, Gativikriti, Avanamana, ADL, Motor Examination, Schwab and England ADL scale and in Group B, significant results were found in Kampa, Chestasanga, Vakavikriti, Mentation, Behaviour and mood, Modified Hoehn and Yahr Staging. Shirobasti and Nasya showed improvements in the signs and symptoms of Kampavata (PD) in both the groups. Both the procedures were efficacious in reducing Activities of Daily Living, thereby improving quality of life in both the groups.


Kampavata, Ksheerbala Taila, Nasya, Parkinson’s disease, Shirobasti

Full Text:



Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015 Aug 29; 386(9996): 896–912p. Available at:

Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin. 1996; 14(2): 317–335p. Available at:

Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003; 348(14): 1356–1364p. Available at: [PubMed]

Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, et al. Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan county, Taiwan. Neurology. 2001; 57(9): 1679–1686p. Available at: [PubMed]

De Lau LM, Breteler MM. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006; 5: 525–535p.

Miller IN, Cronin-Golomb A. Gender differences in Parkinson’s disease: Clinical characteristics and cognition. Mov Disord. 2010; 25: 2695–2703p.

Rumayor MA, Arrieta O, Sotelo J, et al. Female gender but not cigarette smoking delays the onset of Parkinson’s disease. Clin Neurol Neurosurg. 2009; 111: 738–741p.

Jankovic J, Poewe W. Therapies in Parkinson’s disease. Curr Opin Neurol. 2012; 25: 433–447p.

Smith Y, Wichmann T, Factor SA, DeLong MR. Parkinson’s disease therapeutics: New developments and challenges since the introduction of levodopa. Neuropsychopharmacology. 2012; 37: 213–246p.

Simonson W, Hauser RA, Schapira AHV. Role of the pharmacist in the effective management of wearing-off in Parkinson’s disease. Ann Pharmacother. 2007; 41: 1842–1849p.

Van der Marck MA, Bloem BR, Borm GF, et al. Effectiveness of multidisciplinary care for Parkinson’s disease: a randomized, controlled trial. Mov Disord. 2013; 28: 605–611p.

Schrag A, Horsfall L, Walters K, et al. Prediagnostic presentations of Parkinson’s disease in primary care: a case-control study. Lancet Neurol. 2015; 1: 57–64p.

Chen JJ, Swope DM. Parkinson’s disease. In: DiPiro JT, Talbert RL, Yee GC, et al., editors. Pharmacotherapy: A Pathophysiologic Approach. 9th ed. New York, New York: McGraw-Hill; 2014.

Lim SY, Fox SH, Lang AE. Overview of the extranigral aspects of Parkinson disease. Arch Neurol. 2009; 66: 167–172p.

Jellinger KA. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord. 2012; 27: 8–30p.

Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003; 24: 197–211p.

Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol. 2000; 247(suppl2): 3–10p.

Kovari E, Horvath J, Bouras C. Neuropathology of Lewy body disorders. Brain Res Bull. 2009; 80: 203–210p.

Rajeshwar Shastri edited Charak Samhita, Vidyotini hindi commentary part I Sutrasthana chapter 20/11. Varanasi, India: Bharathi Academy; reprinted edition 2001. 399p.

Basavarajeeyam, Krishnamurthy MS. Aeitology - symptomatology and treatment of vatic disorders. Varanasi, India: Chaukhamba Orientalia; first edition 2014. 149p.

Saxena N, ed. Vangasena vol. I 28/155. Varanasi, India: Chaukhamba Krishnadas Academy; 2004. 409p.

Shrivastva S. Sharangadhar Samhita, Uttara Khanda. Varanasi, India: Chaukhamba Orientalia; 2016. 450p.

Sharma R, Sharma S. Sahasrayogam, Tailaprakarana. Delhi, India: Chaukhamba Sanskrit Pratisthana; 2014. 75p.

Vidyanath R, Nishteshwar K. Sahasra Yoga, 2nd ed Taila Prakarana. Varanasi: Chaukhambha Sanskrit Series Office; 2008.110–112p.


  • There are currently no refbacks.